Pacific Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pacific Biosciences (PACB).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

6Buy

5Hold

1Sell

Consensus RatingBuy# Analysts12Avg. Consensus PT$2Upside to Avg. PT+87.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 11, 2026	Barclays	Luke Sergott	PT Raise	Underweight	$1→$2
Apr 14, 2026	Barclays	Luke Sergott	PT Cut	Underweight	$2→$1
Mar 6, 2026	Barclays	Luke Sergott	Downgrade	Equal-Weight→Underweight	$2→$2
Dec 15, 2025	Barclays	Luke Sergott	PT Raise	Equal-Weight	$2→$2
Nov 11, 2025	Piper Sandler	David Westenberg	PT Raise	Neutral	$2→$2
Nov 10, 2025	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$2→$2
Aug 11, 2025	Piper Sandler	David Westenberg	PT Raise	Neutral	$1→$2
Jun 25, 2025	Barclays	Luke Sergott	PT Cut	Equal-Weight	$2→$2
May 15, 2025	Piper Sandler	David Westenberg	PT Cut	Neutral	$2→$1
May 15, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$2
Apr 10, 2025	Canaccord Genuity	Kyle Mikson	Maintained	Buy	$3
Mar 25, 2025	Scotiabank	Sung Ji Nam	PT Cut	Sector Outperform	$6→$2
Feb 20, 2025	Piper Sandler	David Westenberg	PT Cut	Neutral	$3→$2
Feb 18, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Neutral	$2→$2
Feb 18, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$3
Feb 14, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$3
Jan 23, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Neutral	$2→$2
Nov 11, 2024	UBS	John Sourbeer	Downgrade	Buy→Neutral	$2
Nov 11, 2024	Scotiabank	Sung Ji Nam	PT Cut	Sector Outperform	$7→$6
Nov 11, 2024	Piper Sandler	David Westenberg	PT Raise	Neutral	$2→$3

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.

Benzinga Newsdesk

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and raises the price target from $1.5 to $2.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $1.5 to $2.

Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.

Benzinga Newsdesk

The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts

Benzinga Insights

Pacific Biosciences of California Inc

Pacific Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts

People Also Watch

People Also Watch

Benzinga

Benzinga

Pacific Biosciences of California Inc

Pacific Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

PROBarclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

PROBarclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

PROPiper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

PROStephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts

People Also Watch

People Also Watch

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2